Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company focused on pioneering novel cancer therapies. The company specializes in the discovery, development, and commercialization of drugs targeting nuclear export proteins for the treatment of cancer and other significant diseases. Its flagship product, XPOVIO® (selinexor), is a first-in-class, oral exportin 1 (XPO1) inhibitor and is approved in the U.S. for multiple oncology indications. These include combination therapies with Velcade® (bortezomib) and dexamethasone for multiple myeloma, as well as treatments for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Recent achievements highlight the company's commitment to advancing its late-stage clinical pipeline. Notably, Karyopharm has been at the forefront in evaluating selinexor's efficacy in combination therapies for multiple myeloma, endometrial cancer, and myelofibrosis. The company recently reported long-term follow-up data from a Phase 1/3 study on selinexor in combination with ruxolitinib in myelofibrosis patients, showing promising results in spleen volume and symptom reduction.
Financially, Karyopharm reported total revenue of $33.7 million for Q4 2023, with a full-year revenue of $146.0 million. Despite a competitive market, the company managed to maintain steady growth and focused resources on its high-potential pipeline. With a cash position of $192.4 million as of December 31, 2023, Karyopharm is well-positioned to continue its innovative research and development efforts.
Karyopharm's collaborations with global partners, including Antengene, Menarini, Neopharm, and FORUS, have extended the reach of XPOVIO to various international markets such as Europe, China, South Korea, and Israel. This international expansion underscores the global demand for innovative cancer therapies.
For more information, please visit www.karyopharm.com.
Karyopharm Therapeutics (Nasdaq: KPTI) has announced a conference call and webcast scheduled for October 31, 2024, at 8:00 a.m. ET. The event will feature leading myelofibrosis experts Dr. Raajit Rampal from Memorial Sloan Kettering Cancer Center and Dr. John Mascarenhas from Mount Sinai. They will provide a favorable study design update on the company's pivotal Phase 3 SENTRY study in JAKi naive myelofibrosis.
The conference call will be accessible via phone at (800) 836-8184 (local) or (646) 357-8785 (international). A live webcast with slides will be available on the company's investor website, with an archived version available approximately two hours after the event.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company focusing on novel cancer therapies, has announced the granting of 17,000 restricted stock units (RSUs) to three newly-hired employees. These RSU awards were granted on September 30, 2024, under the company's 2022 Inducement Stock Incentive Plan, in compliance with Nasdaq Listing Rule 5635(c)(4).
The RSU awards will vest over a three-year period, with 33 1/3% of the shares vesting on each anniversary of the Grant Date, subject to continued employment. In the event of a "change in control event" followed by termination for "good reason" or without "cause" within one year, the RSUs will become immediately exercisable in full.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company focusing on novel cancer therapies, has announced the granting of 22,050 restricted stock units (RSUs) to five newly-hired employees. These RSU awards, granted on August 31, 2024, are part of the company's 2022 Inducement Stock Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4).
The RSUs will vest over three years, with 33 1/3% vesting on each anniversary of the grant date, subject to continued employment. In case of a 'change in control event' followed by termination under specific conditions within a year, the RSUs will become fully exercisable.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company specializing in novel cancer therapies, has announced its participation in two upcoming investor conferences in September 2024:
- H.C. Wainwright 26th Annual Global Investment Conference on September 10, featuring a podium presentation at 9:00 a.m. ET
- Baird 2024 Global Healthcare Conference on September 11, with a fireside chat at 10:50 a.m. ET
Live webcasts and slides will be available on the company's website. Karyopharm is known for its oral compound XPOVIO® (selinexor), an XPO1 inhibitor approved in the U.S. for three oncology indications and in other countries as NEXPOVIO®. The company focuses on high unmet need cancers, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) reported financial results for Q2 2024, achieving total revenue of $42.8 million and U.S. XPOVIO® net product revenue of $28.0 million. The company highlighted:
1. Updated clinical results from the SIENDO study showing promising PFS in endometrial cancer subgroups.
2. Completion of refinancing transactions extending debt maturities to 2028 and 2029.
3. Raised lower end of 2024 revenue guidance to $145.0-$160.0 million.
4. Lowered 2024 R&D and SG&A expense guidance to $250.0-$265.0 million.
5. Reported net income of $23.8 million for Q2 2024.
6. Cash position of $152.5 million as of June 30, 2024.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has announced the granting of 14,000 restricted stock units (RSUs) to four newly-hired employees. These RSU awards, granted on July 31, 2024, are part of the Company's 2022 Inducement Stock Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over three years, with 33 1/3% vesting on each anniversary of the grant date, subject to continued employment. In the event of a 'change in control,' the RSUs may become fully exercisable if the employee's employment is terminated under specific conditions within one year of the event.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has announced it will report its second quarter 2024 financial results on Tuesday, August 6, 2024. The company's management team will host a conference call and audio webcast at 8:00 a.m. ET on the same day to discuss the financial results and provide company updates.
Investors and interested parties can access the conference call by dialing (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes before the start time. A live audio webcast of the call, along with accompanying slides, will be available on the company's website under the 'Events & Presentations' section. An archived version of the webcast will be accessible approximately two hours after the event.
Karyopharm Therapeutics (Nasdaq: KPTI) has granted 8,800 restricted stock units (RSUs) to three newly-hired employees as of June 30, 2024, under its 2022 Inducement Stock Incentive Plan.
The RSUs are an inducement for employment and will vest over three years, with one-third vesting on each anniversary of the grant date. These awards are subject to the employees' continued service. Additionally, full vesting will occur if employment is terminated for 'good reason' or without 'cause' within one year following a change in control event.
Karyopharm Therapeutics, a commercial-stage pharmaceutical company, announced the grant of 9,500 restricted stock units (RSUs) to three newly-hired employees and 200,000 RSUs to Dr. Michael Method, Senior VP of Clinical Development. These grants, effective May 31, 2024, were made under the 2022 Inducement Stock Incentive Plan and follow Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over three years, contingent on continued employment. Immediate full vesting occurs if employment is terminated for 'good reason' or without 'cause' within one year of a 'change in control event.' Keywords: KPTI, Karyopharm, RSUs, Nasdaq, restricted stock units.
Karyopharm Therapeutics presented updated subgroup analyses from the SIENDO study at the 2024 ASCO Meeting, focusing on advanced or recurrent TP53 wild-type endometrial cancer. Key findings include a median progression-free survival (PFS) of 28.4 months for selinexor-treated patients versus 5.2 months for the placebo group. Additionally, a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis showed a mean of 26 months for selinexor compared to 15 months for placebo. No new safety signals were identified. The exploratory subgroup analysis highlighted promising efficacy signals, with ongoing Phase 3 trials expected to provide definitive results by mid-2025.
FAQ
What is the current stock price of Karyopharm Therapeutics (KPTI)?
What is the market cap of Karyopharm Therapeutics (KPTI)?
What is Karyopharm Therapeutics' main focus?
What is XPOVIO® (selinexor)?
What recent achievements has Karyopharm reported?
Who are Karyopharm's global partners?
What are Karyopharm's financial highlights?
What are the key indications for XPOVIO?
What is the significance of Karyopharm's research on nuclear export proteins?
How does Karyopharm support clinical trials and research?
What are the safety considerations for XPOVIO?
How can I get more information about Karyopharm's products or clinical trials?
